CJ Bio "3 Technology Exports Within 3 Years"... Announces New Vision

Achieving 3 Technology Exports Within 3 Years
Accelerating New Drug Development with AI-Intensive 'EasyM Platform'

CJ Bioscience plans to evolve into an "AI-based Microbiome Global Innovative Company" and aims to achieve three technology exports within the next three years.

CJ Bioscience announced on the 20th that it held the "2024 New Vision Declaration Ceremony" with all employees attending, setting this goal. The new vision is "AI-based Microbiome Global Innovative Company," which signifies leading innovation in new drug development and wellness business sectors through AI-based microbiome science and technology.

Additionally, the company announced a new mission to "contribute to human health through only-one therapeutics and solutions," expressing its ambition to contribute to human health throughout the entire life cycle, from treatment to prevention.

Cheon Jong-sik, CEO of CJ Bioscience, is presenting future plans at the '2024 New Vision Declaration Ceremony' held on the 20th.
[Photo by CJ Bioscience]

Cheon Jong-sik, CEO of CJ Bioscience, stated, "CJ Bioscience has accumulated microbiome data and AI-related capabilities over a long period through continuous acquisition and analysis of clinical data," adding, "With the advent of a new AI era, we will accelerate growth as a microbiome-based global innovative company by transitioning from digital to artificial intelligence."

Along with the vision declaration, CJ Bioscience plans to advance the AI-concentrated "Ez-Mx platform" to accelerate new drug development and discover new businesses. The Ez-Mx platform, based on microbiome big data, is utilized for discovering new drug candidates and biomarkers, enhancing predictive accuracy at all clinical stages, thereby reducing research and development costs and improving clinical success rates.

CJ Bioscience is focusing on new drug development through the Ez-Mx platform. The core pipeline, CJRB-101, is indicated for lung cancer and head and neck cancer in combination therapy with Keytruda, currently undergoing Phase 1 and 2 trials simultaneously in South Korea. Clinical trials are scheduled to begin in the U.S. from the third quarter of this year, with plans to initiate multinational clinical trials. CJ Bioscience plans to prioritize targeting the lung cancer market, expected to reach approximately 56 trillion KRW, with CJRB-101, and aims to achieve three technology exports by 2026 by developing related follow-up pipelines such as degenerative brain disease (CJRB-302) and inflammatory diseases (CJRB-201).

Since its establishment, CJ Bioscience has continuously enhanced its AI capabilities, particularly focusing on accumulating high-quality data, a core element of AI technology. CJ Bioscience possesses industry-leading microbiome big data, clinical data accumulated through joint research with medical institutions and cohort studies, and human-derived sample analysis data. The company plans to further strengthen its AI capabilities by recruiting additional AI experts and expanding its global AI expert network.

A CJ Bioscience official said, "The microbial-based science technology and AI-based platform capabilities we possess are expected to become a pillar of CJ Group's future wellness business," adding, "We will also strengthen synergy with CJ CheilJedang by discussing the concretization of businesses linked to food and health functional foods within this year."

This content was produced with the assistance of AI translation services.